Key result
The prevalence of anemia among patients with cardiorenal syndrome was not significantly different between those with HFpEF and HFrEF (66.2% vs. 57.4%, p=0.2).
Why the study?
To explore patient characteristics of cardiorenal anemia syndrome across different heart failure phenotypes in the Middle East Region.
Observational (n=230)
No
Absolute Event Rate: 66.2% vs 57.4%
p-value: p=0.2
In a Middle Eastern cohort of patients with cardiorenal syndrome, anemia is highly prevalent (60%) and occurs at similar rates in both HFrEF and HFpEF.
Comparable anemia prevalence in cardiorenal syndrome across HF phenotypes supports uniform screening; leaves open differential prognostic or therapeutic implications by ejection fraction.
Background: Patients with cardiorenal syndrome (CRS) have an increased risk of developing anemia, resulting in cardiorenal anemia syndrome (CRAS), which can lead to worsening renal and cardiac functions. This gets more complicated when multiple systemic conditions co-exist, such as in heart failure with preserved ejection fraction (HFpEF). To better understand the interplay between anemia, the heart, and the kidney, we aim to explore patients' characteristics of CRAS within different heart failure (HF) phenotypes, in the Middle East Region. Methods: We included HF patients having stage 3-5 CKD (n=230) at their first visit to our HF clinic from October 2015 to January 2019. Patient characteristics were collected by a retrospective chart review. A comparison was made between HFrEF and HFpEF in CRAS patients in terms of baseline characteristics and iron deficiency anemia surrogates using appropriate parametric or non-parametric (for skewed variables) testing methods, and a p-value< 0.05 was considered statistically significant. Results: Among 230 patients with cardiorenal syndrome, 138 (60%) of patients had anemia (Hb<120 g/L). There was no significant difference in the prevalence of anemia in the HFrEF- CRS group vs. HFpEF- CRS group (57.4% vs. 66.2%, p=0.2). When comparing HFrEF- CRAS patients with HFpEF- CRAS patients, the HFpEF group were more likely females, had lower hemoglobin, and higher rates of cardiovascular co-morbidities (Table). Furthermore, there was no significant difference in iron deficiency parameters between the two groups. Conclusions: In this part of the world, where cardio-renal-metabolic conditions are highly prevalent, the prevalence of anemia among CRS patients is comparable to western countries and it was comparable among HFpEF and HFrEF CRS patientsTable.: Baseline characteristics of patients with cardiorenal anemia syndrome according to their heart failure phenotype
No takes yet. Share an insight, caveat, or question.
Manla et al. (2021) conducted an observational in Cardiorenal syndrome in heart failure (n=230). Heart failure with preserved ejection fraction (HFpEF) vs. Heart failure with reduced ejection fraction (HFrEF) was evaluated on Prevalence of anemia (Hb<120 g/L) (p=0.2). The prevalence of anemia among patients with cardiorenal syndrome was not significantly different between those with HFpEF and HFrEF (66.2% vs. 57.4%, p=0.2).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: